MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · IEX Real-Time Price · USD
1.010
-0.030 (-2.88%)
At close: May 17, 2024, 4:00 PM
1.060
+0.050 (4.95%)
After-hours: May 17, 2024, 7:21 PM EDT
Company Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York.
MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
MiNK Therapeutics, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Dr. Jennifer S. Buell Ph.D. |
Contact Details
Address: 149 Fifth Avenue, Suite 500 New York, New York 10010 United States | |
| Phone | 212-994-8250 |
| Website | minktherapeutics.com |
Stock Details
| Ticker Symbol | INKT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001840229 |
| CUSIP Number | 603693102 |
| ISIN Number | US6036931029 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Garo H. Armen Ph.D. | Executive Chairman |
| Dr. Jennifer S. Buell Ph.D. | President, Chief Executive Officer and Director |
| Dr. Marcus Antonius van Dijk Ph.D. | Chief Scientific Officer |
| Christine M. Klaskin | Treasurer |
| Joy Zhou Ph.D. | Vice President and Head of CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 16, 2024 | 8-K | Current Report |
| May 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| Apr 30, 2024 | ARS | Filing |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Feb 14, 2024 | 8-K | Current Report |